sFlt-1 Biomarker Screening for Early Preeclampsia Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting and assessing the risk of preeclampsia, particularly early onset preeclampsia, are complex and often require uterine artery Doppler measurements, which are not universally available. There is a need for simplified and reliable molecular diagnostic approaches that can accurately predict preeclampsia in early pregnancy.
Innovation Solution
The method involves determining the level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragments thereof in a sample from a pregnant subject before the end of the 12th week of gestation. This level is indicative of the likelihood of early onset preeclampsia occurring before the end of the 33rd week of gestation. Additionally, the method may include measuring placental growth factor (PlGF) and considering maternal age, body mass index, uterine artery doppler measurement, and mean arterial pressure to enhance predictive accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for predicting and assessing the risk of preeclampsia are used, then prediction accuracy can be achieved, but the complexity of the screening process increases and requires specialized equipment (uterine artery Doppler measurements) that is not universally available
Solution Approach 1:
The patent extracts the essential predictive function from complex Doppler ultrasound equipment and transfers it to simple blood biomarker measurements. By identifying specific biomarkers (sFlt-1, PlGF, PAPP-A) that can be measured in routine blood tests, the invention removes the dependency on specialized Doppler equipment while maintaining prediction capability for early onset preeclampsia
Solution Approach 2:
The patent replaces the mechanical ultrasound-based Doppler measurement system with a biochemical analysis system. Instead of using mechanical waves to measure uterine artery flow, the invention uses laboratory blood tests to measure biomarker concentrations, substituting a complex mechanical diagnostic system with a simpler biochemical assay approach
2Measurement precision
If uterine artery Doppler measurements are required for preeclampsia screening, then diagnostic accuracy is improved, but accessibility to screening deteriorates due to limited availability of specialized equipment
Solution Approach 1:
The patent makes preeclampsia screening universally accessible by using biomarkers that can be measured in routine blood tests already performed during prenatal care. The same laboratory infrastructure used for standard pregnancy blood work can now also perform preeclampsia risk assessment, eliminating the need for specialized Doppler equipment and making screening available in any facility that performs routine prenatal blood tests
3Reliability
If multiple biomarkers and additional factors are measured to enhance predictive accuracy, then prognosis reliability is improved, but the quantity of measurements and complexity increases
Solution Approach 1:
The patent merges multiple predictive functions into a single integrated risk assessment model. By combining measurements of sFlt-1, PlGF, and PAPP-A biomarkers with standard clinical factors (maternal age, BMI, blood pressure) in one unified algorithm, the invention achieves comprehensive prognosis while using measurements that are already part of routine prenatal care, avoiding the need for separate specialized tests
Data Source
AI summary
A method for treating a subject to reduce the risk of early onset preeclampsia in a pregnant subject determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The the sample is isolated from a subject before the end of the 12th week of gestation, where the level of sFlt-1 or fragment(s) thereof is indicative of early onset preeclampsia occurring before the end of the 33rd week of gestation. The subject is then treated to decrease the risk of developing, delay the time point of the onset and/or reduce the severity of preeclampsia.